Published in Mol Ther on August 28, 2007
Integrase, LEDGF/p75 and HIV replication. Cell Mol Life Sci (2008) 1.50
Retroviral integrations in gene therapy trials. Mol Ther (2012) 1.34
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
The therapeutic potential of stem cells. Philos Trans R Soc Lond B Biol Sci (2010) 1.15
Retroviral integration site selection. Viruses (2010) 1.10
Autonomous targeting of infectious superspreaders using engineered transmissible therapies. PLoS Comput Biol (2011) 1.10
Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis. PLoS One (2011) 1.05
Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells. PLoS One (2009) 1.03
Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev Anticancer Ther (2009) 0.97
The Oncogenic Potential of Mesenchymal Stem Cells in the Treatment of Cancer: Directions for Future Research. Curr Immunol Rev (2010) 0.93
Oligo/polynucleotide-based gene modification: strategies and therapeutic potential. Oligonucleotides (2011) 0.87
LMO2 at 25 years: a paradigm of chromosomal translocation proteins. Open Biol (2015) 0.86
Gene therapy in thalassemia and hemoglobinopathies. Mediterr J Hematol Infect Dis (2009) 0.86
Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. ISRN Oncol (2012) 0.82
Recent advances in gene therapy for severe congenital immunodeficiency diseases. Curr Opin Hematol (2008) 0.80
Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases. J Diabetes Investig (2011) 0.79
Identification of a high incidence region for retroviral vector integration near exon 1 of the LMO2 locus. Retrovirology (2009) 0.78
Rebalancing immune specificity and function in cancer by T-cell receptor gene therapy. Arch Immunol Ther Exp (Warsz) (2010) 0.78
Promoted Growth of Brain Tumor by the Transplantation of Neural Stem/Progenitor Cells Facilitated by CXCL12. Transl Oncol (2014) 0.76
Lentiviral hematopoietic stem cell gene therapy in inherited metabolic disorders. Hum Gene Ther (2014) 0.76
Exploiting Genetic Interference for Antiviral Therapy. PLoS Genet (2016) 0.76
Hotspots of MLV integration in the hematopoietic tumor genome. Oncogene (2016) 0.75
Serial bone marrow transplantation reveals in vivo expression of the pCLPG retroviral vector. Virol J (2010) 0.75
Characterization of Equine Infectious Anemia Virus Integration in the Horse Genome. Viruses (2015) 0.75
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes (2004) 4.24
The 3D structure of the immunoglobulin heavy-chain locus: implications for long-range genomic interactions. Cell (2008) 3.92
Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest (2007) 3.28
The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J Exp Med (2011) 2.96
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet (2004) 2.82
Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest (2007) 2.80
An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med (2006) 2.77
New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med (2005) 2.44
Wnt3a deficiency irreversibly impairs hematopoietic stem cell self-renewal and leads to defects in progenitor cell differentiation. Blood (2008) 2.37
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood (2011) 2.18
Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. Cell Stem Cell (2011) 2.18
Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood (2011) 2.15
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer (2005) 2.08
Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J Exp Med (2007) 2.05
Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways. Blood (2006) 1.98
Circulating CD21low B cells in common variable immunodeficiency resemble tissue homing, innate-like B cells. Proc Natl Acad Sci U S A (2009) 1.91
A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining. J Clin Invest (2008) 1.82
CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J Clin Invest (2010) 1.79
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol (2011) 1.71
A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch Gen Psychiatry (2008) 1.66
Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol Ther (2004) 1.65
Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood (2005) 1.63
Ig gene rearrangement steps are initiated in early human precursor B cell subsets and correlate with specific transcription factor expression. J Immunol (2005) 1.61
A new type of radiosensitive T-B-NK+ severe combined immunodeficiency caused by a LIG4 mutation. J Clin Invest (2005) 1.59
Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. Blood (2011) 1.53
The effect of a novel recombination between the homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the NKX2-5 gene. Haematologica (2006) 1.52
Anti-TNF treatment blocks the induction of T cell-dependent humoral responses. Ann Rheum Dis (2012) 1.51
Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood (2002) 1.45
Wnt target genes identified by DNA microarrays in immature CD34+ thymocytes regulate proliferation and cell adhesion. J Immunol (2004) 1.41
Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Res (2014) 1.40
Contrasting responses of lymphoid progenitors to canonical and noncanonical Wnt signals. J Immunol (2008) 1.29
Human thymus contains multipotent progenitors with T/B lymphoid, myeloid, and erythroid lineage potential. Blood (2005) 1.29
Distinct monocyte gene-expression profiles in autoimmune diabetes. Diabetes (2008) 1.25
Wnt signaling in the thymus is regulated by differential expression of intracellular signaling molecules. Proc Natl Acad Sci U S A (2006) 1.24
Mutations in ZBTB24 are associated with immunodeficiency, centromeric instability, and facial anomalies syndrome type 2. Am J Hum Genet (2011) 1.24
Radiosensitive SCID patients with Artemis gene mutations show a complete B-cell differentiation arrest at the pre-B-cell receptor checkpoint in bone marrow. Blood (2002) 1.23
The nature of circulating CD27+CD43+ B cells. J Exp Med (2011) 1.22
Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection. Clin Cancer Res (2005) 1.21
B-cell replication history and somatic hypermutation status identify distinct pathophysiologic backgrounds in common variable immunodeficiency. Blood (2011) 1.19
Gene therapy: is IL2RG oncogenic in T-cell development? Nature (2006) 1.18
BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J Mol Diagn (2005) 1.17
Generation of flow cytometry data files with a potentially infinite number of dimensions. Cytometry A (2008) 1.16
Different chromosomal breakpoints impact the level of LMO2 expression in T-ALL. Blood (2007) 1.15
Canonical Wnt signaling negatively modulates regulatory T cell function. Immunity (2013) 1.13
Gross deletions involving IGHM, BTK, or Artemis: a model for genomic lesions mediated by transposable elements. Am J Hum Genet (2008) 1.12
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood (2007) 1.11
Allelotype analysis in relapsed childhood acute lymphoblastic leukemia. Oncogene (2003) 1.11
Classification systems for acute and chronic leukaemias. Best Pract Res Clin Haematol (2003) 1.09
Morbidly obese human subjects have increased peripheral blood CD4+ T cells with skewing toward a Treg- and Th2-dominated phenotype. Diabetes (2012) 1.09
Breakpoint sites disclose the role of the V(D)J recombination machinery in the formation of T-cell receptor (TCR) and non-TCR associated aberrations in T-cell acute lymphoblastic leukemia. Haematologica (2013) 1.08
Age-related changes in the cellular composition of the thymus in children. J Allergy Clin Immunol (2005) 1.07
Diagnosing mycobacterial lymphadenitis in children using fine needle aspiration biopsy: cytomorphology, ZN staining and autofluorescence -- making more of less. Diagn Cytopathol (2008) 1.07
Endothelial progenitor cell dysfunction in type 1 diabetes: another consequence of oxidative stress? Antioxid Redox Signal (2005) 1.07
The nuclear effector of Wnt-signaling, Tcf1, functions as a T-cell-specific tumor suppressor for development of lymphomas. PLoS Biol (2012) 1.06
Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther (2011) 1.04
Unraveling of the polymorphic C lambda 2-C lambda 3 amplification and the Ke+Oz- polymorphism in the human Ig lambda locus. J Immunol (2002) 1.04
Unraveling the consecutive recombination events in the human IGK locus. J Immunol (2004) 1.04
Wnt signaling and phosphorylation status of beta-catenin: importance of the correct antibody tools. Blood (2007) 1.03
Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. J Exp Med (2010) 1.03
Pitfalls in TCR gene clonality testing: teaching cases. J Hematop (2008) 1.03
Heterogeneous clinical presentation in ICF syndrome: correlation with underlying gene defects. Eur J Hum Genet (2013) 1.02
Overview of clinical flow cytometry data analysis: recent advances and future challenges. Trends Biotechnol (2013) 1.01
Composition of precursor B-cell compartment in bone marrow from patients with X-linked agammaglobulinemia compared with healthy children. Pediatr Res (2002) 1.01
Clinical heterogeneity can hamper the diagnosis of patients with ZAP70 deficiency. Eur J Pediatr (2008) 1.00
Wiskott-Aldrich syndrome protein-mediated actin dynamics control type-I interferon production in plasmacytoid dendritic cells. J Exp Med (2013) 1.00